Merck & Co., Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Merck & Co., Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 4.5 times. Higher than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$143Over the last 3 years, every $100 of reported profit came with $143 of operating cash.
Lower than 54% of Healthcare companies in United States.
Self-Funding Ratio
4.5×Over the last 3 years its own operating cash covered its investment spending (capex) 4.5 times.
Higher than 85% of Healthcare companies in United States.
Cash Locked Ratio
$11For every $100 of sales, $11 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $12 tied up three years earlier.
Less money tied up than 78% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$65Sales grew 10% in 3 years; of every extra $100 of sales, $65 became extra profit.
Higher than 75% of Healthcare companies in United States.
Asset Productivity Ratio
+10% / +25%In 3 years sales changed by +10% while total assets changed by +25%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
6.4×Debt due within a year is covered 6.4 times by its yearly operating cash.
Higher than 82% of Healthcare companies in United States.
Cash Cushion Ratio
−10%Debt, after subtracting cash, equals 10% of its market value (net debt).
Lower than 78% of Healthcare companies in United States.
Tangible Assets Ratio
65%Of every $100 the company owns, $65 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 66% of Healthcare companies in United States.
Tangible Net Worth Ratio
8%Of every $100 of net worth, $8 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 70% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Merck & Co., Inc. owes $0.68 for every $1 it owns. Net profit rose 7% in the year to Dec 2025, and grew 8% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
117.2Investors pay $117.2 for every $1 of Merck & Co., Inc.'s yearly profit, higher than 92% of Healthcare companies in United States.
P/B ratio
8.55The share price is 8.55 times Merck & Co., Inc.'s book value per share, higher than 84% of Healthcare companies in United States.
Market cap
$358.4 BThe total market value of all of Merck & Co., Inc.'s shares at today's price (share price × number of shares), larger than almost all Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$41.9 BWhat Merck & Co., Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$17.00Net worth divided by the number of shares. The share price of $145.27 is 8.5 times this, which is the P/B above.
Return on equity (ROE)
7.0%Merck & Co., Inc. earned 7.0% on its shareholders' money over the last year, higher than 81% of Healthcare companies in United States.
Owes vs Owns
0.68×Merck & Co., Inc. owes $0.68 for every $1 it owns (moderate), higher than 71% of Healthcare companies in United States.
Dividend yield
2.31%Merck & Co., Inc. pays 2.31% of its share price as dividends a year, higher than 82% of dividend-paying Healthcare companies in United States.
Revenue growth
+1%Revenue rose 1% in the year to Dec 2025, and grew 3% a year on average over 3 years.
Profit growth
+7%Net profit rose 7% in the year to Dec 2025, and grew 8% a year on average over 3 years.
Profit margin
28.1%Merck & Co., Inc. keeps $28 of every $100 of revenue as net profit.
Cash quality
0.90×Cash from Merck & Co., Inc.'s business was 0.90× its reported profit in the year to Dec 2025 — less cash came in than the profit reported.
Interest cover
16.3×Merck & Co., Inc.'s operating profit covered its interest costs 16.3 times in the year to Dec 2025.
Cash vs debt
Net debtMerck & Co., Inc. had $34.8 B more debt than cash (net debt) at Dec 2025.
Questions
What is Merck & Co., Inc.'s P/E ratio?
Investors pay $117.2 for every $1 of Merck & Co., Inc.'s yearly profit, higher than 92% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Merck & Co., Inc.: $358.4 B ÷ $41.9 B (30 Jun 2026) = 8.5.
What is Merck & Co., Inc.'s return on equity?
Merck & Co., Inc. earned 7.0% on its shareholders' money over the last year, higher than 81% of Healthcare companies in United States.
How much does Merck & Co., Inc. owe compared with what it owns?
Merck & Co., Inc. owes $0.68 for every $1 it owns (moderate), higher than 71% of Healthcare companies in United States.
Does Merck & Co., Inc. pay a dividend?
Yes. Merck & Co., Inc. pays 2.31% of its share price as dividends a year, higher than 82% of dividend-paying Healthcare companies in United States.
Is Merck & Co., Inc.'s revenue growing?
Revenue rose 1% in the year to Dec 2025, and grew 3% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.